Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EDEMA4: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema

NCT00457015 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00457015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00457015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EDEMA4: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2007
Completion date
June 1, 2008
Enrollment
96 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)